Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zolinza (vorinostat)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Merck (MSD)

Drug class:

HDAC inhibitor

Related drugs:

‹

›

No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1
GNAQ mutation	Melanoma	GNAQ mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
GNA11 mutation	Melanoma	GNA11 mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
BAP1 mutation	Melanoma	BAP1 mutation	Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2	vorinostat Sensitive: C2 – Inclusion Criteria vorinostat Sensitive : C2
KMT2A-PTD	Acute Myelogenous Leukemia	KMT2A-PTD	Acute Myelogenous Leukemia	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3
BRAF V600	Melanoma	BRAF V600	Melanoma	vorinostat Sensitive: C3 – Early Trials vorinostat Sensitive : C3	vorinostat Sensitive: C3 – Early Trials vorinostat Sensitive : C3
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vorinostat Sensitive: C3 – Early Trials vorinostat Sensitive : C3	vorinostat Sensitive: C3 – Early Trials vorinostat Sensitive : C3
KMT2A rearrangement	B Acute Lymphoblastic Leukemia	KMT2A rearrangement	B Acute Lymphoblastic Leukemia	bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive: C3 – Early Trials bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive : C3	bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive: C3 – Early Trials bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive : C3
RAD23B overexpression	Soft Tissue Sarcoma	RAD23B overexpression	Soft Tissue Sarcoma	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D
SOCS1 overexpression	Hepatocellular Cancer	SOCS1 overexpression	Hepatocellular Cancer	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D
GSTP1 overexpression	Hepatocellular Cancer	GSTP1 overexpression	Hepatocellular Cancer	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D
HDAC1 underexpression	Hepatocellular Cancer	HDAC1 underexpression	Hepatocellular Cancer	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D	vorinostat Sensitive: D – Preclinical vorinostat Sensitive : D